Omeros Corporation

-0.15 (-2.02%)


Draw Mode:

Volume 469,553
Bid Price 7.25
Ask Price 7.26
News -
Day High 7.7975


52 Week Range


Day Low 7.23
Company Name Stock Ticker Symbol Market Type
Omeros Corporation OMER NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.15 -2.02% 7.26 15:58:34
Open Price Low Price High Price Close Price Prev Close
7.45 7.23 7.7975 7.41
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
5,935 469,553 $ 7.46 $ 3,502,180 - 1.735 - 7.7975
Last Trade Time Type Quantity Stock Price Currency
15:58:36 50 $ 7.25 USD

Omeros Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 456.14M 62.83M 62.80M $ 375.00k $ -337.01k - -1,353.47
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 4.10%

more financials information »

Omeros News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No OMER Message Board. Create One! See More Posts on OMER Message Board See More Message Board Posts

Historical OMER Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week5.797.79755.787.03648,9311.4725.39%
1 Month5.157.79754.846.13606,2302.1140.97%
3 Months3.287.79753.0515.50510,3163.98121.34%
6 Months2.047.79751.7354.46765,7175.22255.88%
1 Year2.527.79751.7354.05832,0574.74188.1%
3 Years14.6825.491.7359.17865,631-7.42-50.54%
5 Years19.8027.001.73511.36758,903-12.54-63.33%

Omeros Description

Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders.